Enjoy a day in Greenwich
dedicated to Breast Cancer Awareness Month
Thursday, October 2
Mention Go For Pink and a donation will be made to Breast Cancer Alliance at participating merchants*
Attend Go For Pink ~ sip, shop and support as a community throughout the day
Support Go For Pink ~ shopping receptions from 5-8PM and at Richards of Greenwich from 5-9PM
Breast Cancer Alliance flag raising at Town Hall at 9AM ~ First Selectman Peter Tesei plans to attend
Participating Merchants to date include:
Alease Fisher, Amina Rubinacci, Anne Fontaine, CLAY, Comptoir des Cotonniers, Equinox, French Sole, Gabby, Hoagland’s of Greenwich, J. Papers, Kate Spade, Lilly Pulitzer, Lynnens, McArdles, OGGI 5, R. Simatov, Richards, Simon Pearce, Splurge, Steven Fox Jewelry, Stuart Weitzman, Tangerine, Theory, Tory Burch, Vilebrequin, Vineyard Vines and Warren Tricomi
*The list of merchants will be updated as the event nears
**If you are a merchant and would like to get involved, please click on the links below to download additional information:
Members of the 2014 benefit committee, co-chaired by Lisa Fischer and Jieun Wax, enjoyed a beautiful working lunch at Winston Flowers on Thursday, June 12.
Rosie of New Canaan catered the event, while Val’s Liquors offered a few wine pairings, and Roshi of Greenwich-based Sorab + Roshi previewed 2 pair of gorgeous custom earrings in anticipation of this year’s silent auction.
We look forward to seeing you on November 6! To purchase patron-level tickets now, please contact email@example.com or call the BCA office, 203.861.0014.
Photos courtesy of Bob Capazzo
On May 21, Moffly Media hosted its annual Women in Business event at the Stamford Hilton, and proceeds were designated for Breast Cancer Alliance once again. Becky Surran was this year’s moderator of a panel on women’s entrepreneurship, whose speakers included Robin Selden of Marcia Selden Catering, Brett Galley of Hollywood Pop Gallery and Joan Lunden, businesswoman and former co-host of GMA. For highlights of the event, go to:Read More
Click here to read the latest issue of our newsletter, Outlook, online! If you prefer to receive a hard copy, please contact the office to be sure you are on our mailing list at firstname.lastname@example.org.Read More
Each year, in accordance with our commitment to due diligence, we visit each of the institutions to whom we provide a grant allocation.
The remaining dates for this year’s visits are listed below. If you would like to attend one of these visits, or receive more information about timing and content, please contact Crystal Stoute, Executive Assistant, at email@example.com.
September 9: Gilda’s Club
September 16: Norma F. Pfriem Breast Care Center, St. Vincent’s Hospital and The Witness Project
Thomas Jefferson University, Hallgeir Rui: Dr. Rui has developed a mouse model, expressing human prolactin hormone, that is duplicative of the human system with breast cancer. This model is being used to test the efficacy of prolactin suppression alone or in combination with anti-estrogens on lung metastases after removal of a primary tumor.
Columbia University, Jose M. Silva: This study aims to analyze the genetic fingerprint of inflammatory breast cancer, and identify those alterations that are associated with tumorigenicity, with an eye to identifying new targets for treatment.
Weill Medical College of Cornell University, Lewis (Lew) S. Cantley (with Gerburg M. Wulf on skype): Dr. Cantley and Dr. Wulf are using mouse models to determine which combinations of PI3K (a known cancer promoter) inhibitors and other chemotherapeutic agents have a beneficial effect on cancers that do not respond to estrogen receptor blockers or Her-2 blocking agents.
October 14: Stamford Hospital
Dana-Farber Cancer Institute
Constantine S. Mitsiades: Dr. Mitsiades has previously observed that “accessory” non-metastatic cells aid metastatic cells in their resistance to chemotherapy. The present study is examining the mechanisms by which these accessory cells may work in aiding estrogen-receptor mutated tumor cells in becoming resistant to anti-estrogen therapies, in the context of bone metastases, the most common, but infrequently studied, of breast cancer metastatic sites.
Kornelia (Nelly) Polyak: Based on prior observations of metabolic differences between tumor cells and normal cells, Dr. Polyak’s study is looking at the role that metabolic changes induced by stromal (normal) cells play in the development of tumor cells’ therapeutic resistance, with an aim to identify possible metabolic pathways as therapeutic targets.Read More